FDA endorses accuracy of microarray tech

The FDA's Microarray Quality Control project has delivered a badly needed endorsement of the microarray technologies out on the market. Spurred by studies that suggested varying results among the different microarrays on the market, the FDA set out to determine how accurate they were in delivering results. Microarrays have played an enormous role in identifying a new generation of drug leads, helping spur the development of the biotech industry. The agency found that the microarrays delivered consistent results, which should lift the suspicion that the data delivered could be fundamentally erroneous. But don't expect the FDA to release a ranking of devices by quality. Different devices work in different ways.

- read the report [1] on microarrays from the San Francisco Chronicle